Market & Forensics Analyst, Beat the Street

Nimish Maheshwari

Nimish Maheshwari, an independent analyst and co-founder of Beat The Street, is an investing platform garnering more than 1,00,000+ followers across social media. 
His deep insights and forensic analysis have been featured in some of India's most prominent publications, including the Economic Times, The Morning Context, The Ken,  Dalal Street Investment Journal, Moneylife by Sucheta Dalal, and TheCore.in.
He has a keen eye for identifying red flags in Indian listed companies and has identified exclusive red flags earlier in Adani, Vedanta, Nykaa, Gland Pharma, Brightcom Group etc.

Market & Forensics Analyst

ITC: Tobacco Volumes to Be Impacted by Increased Taxes; Uncertainty Ahead

Indian Steel: Safeguard Duty Unleashed— A 12% Firewall for the Domestic Bull Run

India’s Steel Surge Is Rewriting the Playbook: Is Tata Steel Poised for the Next Growth Phase?

The Beat Ideas: Meesho Ltd- Deciphering India’s Value-E-Commerce Giant

The Beat Ideas: Welspun Corp - The Three-Continent Infrastructure Proxy, Rerating Beyond Cyclicality

The Beat Ideas: Sequent Scientific Merger - CDMO Optionality with Margin Upside

The Beat Ideas: Kaynes Technology’s Valuation Reset- An Investment Opportunity

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

Entero Healthcare Solutions / Equity Bottom-Up

<ul>
<li>Entero Healthcare differentiates itself through a dual-value model that combines large-scale demand fulfillment with integrated commercial solutions with a massive TAM of <strong>INR 3.3 Trillions.</strong>
</li>
<li>Management is aggressively targeting the high-margin MedTech segment, with revenue from this vertical expected to cross <strong>INR 1,000 crore</strong> on an annualized basis.</li>
<li>Entero is becoming positive operating cash flow in H2FY26 supported by reduction Net Operating Working Capital from 69 to 60 days. </li>
</ul>


Entero Healthcare differentiates itself through a dual-value model that combines large-scale demand fulfillment with integrated commercial solutions with a massive TAM of INR 3.3 Trillions.

Management is aggressively targeting the high-margin MedTech segment, with revenue from this vertical expected to cross INR 1,000 crore on an annualized basis.
Entero is becoming positive operating cash flow in H2FY26 supported by reduction Net Operating Working Capital from 69 to 60 days. 


Entero Healthcare: New Titan of Pharma Distribution